Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor ...
Nov 8, 2025 · Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety profile comparable to placebo Enlicitide …
Enlicitide decanoate - Wikipedia
Enlicitide decanoate (previously known as MK-0616[1]) is an orally available macrocyclic peptide investigational drug that is being evaluated for the treatment of hypercholesterolaemia.
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With ...
Nov 9, 2025 · Objective: To evaluate the efficacy of enlicitide decanoate (an oral proprotein convertase subtilisin/kexin type 9 inhibitor) vs placebo in adults with HeFH requiring further lowering of LDL-C …
Enlicitide: New Drug Cuts LDL Cholesterol By 60 Percent, Offers Fresh ...
Nov 29, 2025 · Summary Enlicitide is an investigational oral PCSK9 inhibitor that has shown substantial reductions in LDL-C levels in patients with elevated cholesterol, including those who are statin …
Enlicitide Decanoate Demonstrates Meaningful Reductions in LDL-C
Jun 13, 2025 · In 3 phase 3 clinical trials, enlicitide decanoate demonstrated clinically significant reductions in low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidemia and familial …
Oral PCSK9 Inhibitor Enlicitide Reduces LDL-C in Adults With ...
Sep 12, 2025 · Enlicitide, designed to deliver antibody-like efficacy, is the first oral macrocyclic peptide PCSK9 inhibitor with clinically meaningful and statistically significant LDL-C lowering in phase 3 …
Oral PCSK9 Inhibitor Enlicitide Matches Injectables in Lowering LDL ...
Nov 8, 2025 · Enlicitide, an oral PCSK9 inhibitor, reduced LDL-C by nearly 60% in adults with or at risk for ASCVD. The medication offers a daily oral alternative to injectable PCSK9 inhibitors, potentially ...
Phase III Trials Show Merck’s Oral PCSK9 Inhibitor Significantly ...
Jun 9, 2025 · How Did Enlicitide Perform in the CORALreef Trials? “We are thrilled to bring forward the first Phase III results from our clinical development program evaluating enlicitide, which, if approved, …
Enlicitide Reduces LDL-C in People With Hyperlipidemia, HeFH, …
Jun 9, 2025 · Enlicitide decanoate is an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor being evaluated in people with hyperlipidemia and heterozygous familial …
MSD’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor ...
Nov 8, 2025 · Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety profile comparable to placebo Enlicitide …